Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.71 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 7/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.53 |
| ▸ | MTOR | P42345 | 2/20 | 0.53 |
| ▸ | NEK2 | P51955 | 1/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14144197 | 0.88 | KDR (0.70) | KDRGABRG2GABRB3GABRA3FLT3 | |
| SCHEMBL17556214 | 0.86 | KDR (0.82) | KDRFLT3FGFR3 | |
| SCHEMBL3379605 | 0.86 | KDR (0.67) | KDRGABRG2GABRB3GABRA3FLT3 | |
| SCHEMBL3186080 | 0.85 | KDR (0.74) | KDRFLT3PIK3CAMTORFGFR3 | |
| SCHEMBL5251547 | 0.83 | KDR (1.00) | KDRGABRG2GABRB3GABRA3FLT3 | |
| SCHEMBL3328696 | 0.82 | KDR (0.80) | KDRGABRG2GABRB3GABRA3FLT3 | |
| SCHEMBL14144255 | 0.82 | KDR (0.80) | KDRGABRG2GABRB3GABRA3FLT3 | |
| SCHEMBL16588365 | 0.81 | GABRG2 (0.83) | KDRGABRG2GABRB3GABRA3FLT3 | |
| SCHEMBL3382949 | 0.80 | FLT3 (0.58) | KDRFLT3FGFR3 | |
| SCHEMBL3384492 | 0.79 | KDR (0.57) | KDRFLT3FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101128461-B | Imidazo (1, 2-a) pyridine compounds as VEGF-R2 inhibitors | LILLY CO ELI | 2010-12-22 | — | — | CN | disclosed |
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| CN-101128461-A | Imidazo (1, 2-a) pyridine compounds as VEGF-R2 inhibitors | LILLY CO ELI (US) | 2008-02-20 | — | — | CN | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | KDR 1/4885GABRG2 852/4885GABRB3 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.